FemTech Leader Willow ® Adds Diverse Set Of Investors In Extended Series C Round

Willow, the company forever changing the way moms pump with the world’s first all-in-one, in-bra wearable breast pump with full spill-proof mobility, today announced an additional $26.8 Million in funding through a Series C Extension round –  led by Endeavour Vision, alongside NEA (New Enterprise Associates), Pura Vida Investments, Purple Arch Ventures (a part of Alumni Ventures Group), Logos Capital, and Gaingels.

This extension brings Willow’s total Series C investment to $81.8 Million.  With the most innovative breast pump on the market, Willow will use its latest growth capital funding to invest in new products and further expand its reach.

“We are excited to lead Willow’s Series C extension to further support the accelerated growth ahead for the company,” said Rob Barmann, Partner at Endeavour Vision. “As the innovation leader in its category, we believe that Willow will continue to develop groundbreaking innovations that disrupt the FemTech and MedTech industries.”

Recognizing that the functionality of breast pumps hadn’t changed in decades, Willow became a pioneer in the FemTech category by reinventing the breast pump. Willow’s proprietary, patented technology offers 100% spill-proof mobility for pumping moms, giving them freedom, dignity, and enabling joy in an otherwise stress-inducing aspect of motherhood.

“I’m excited about the growth we’ve been able to accomplish, and impact we’ve had, in such a short time, towards our mission of bringing joy to motherhood,” said Willow CEO, Laura Chambers. “With this additional funding, we will expand our international presence, grow brand awareness, and accelerate our innovative R&D pipeline of products that solve real problems for moms.”

Willow launched as a direct-to-consumer brand, bringing life-changing technology to women experiencing new motherhood.  Willow has since expanded to reach moms through retail and insurance channels, and was the fastest-growing brand in 2020 in retail for breastfeeding systems, according to NPD Group.  Its innovative breast pump has impacted more than 130,000 moms and counting.

SourceWillow®

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”